Rösch AG Medizintechnik
Rösch AG Medizintechnik english
Rösch AG: restructuring measures as part of strategic focussing
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
Rösch AG: restructuring measures as part of strategic focussing
Budget figures for the 2001/2002, 2002/2003, 2003/2004 financial years
Rösch AG announces the following measures as part of strategic focussing on the
business area of needle-free injection and monitoring systems:Rösch AG is
discontinuing its activities in the Dental area. The 100% subsidiaries mdc GmbH
and mdc KG, on which the dental sector concentrated, will discontinue its
business activities by July 31, 02, at the latest. This will result in valuation
adjustments to the group result of EUR 5.5 million for write-downs from
goodwill and provisions as well as other restructuring expenditure flowing into
the group result in the 01/02 financial year. All identifiable risks arising
from the restructuring measures have thus been taken into account. Furthermore,
the Management Board has resolved to discontinue the business activities of the
100 % subsidiary Acanthos GmbH (sales with nursing services) with immediate
effect. The transfer of expertise to Rösch AG is complete. The important
customer relationship in the Nursing Services area as a service provider to the
health insurance companies is controlled centrally from Berlin by Rösch AG. Due
to the discontinuation of the dental sector the number of employees will drop to
49. The savings thus initiated will allow for a positive budget result for
Rösch AG in the second quarter of the 02/03 financial year.
The participation in Ritter Concept GmbH (44 %) will continue as a purely
financial participation. It generated a slightly positive result in the period
from mid-September to December 31, 01 and sales of approx. EUR 2 million.
Rösch AG is thus underlining its focus on the needle-free technologies area and
the resulting orientation as a research, development and co-operation partner
for the pharmaceutical industry. Rösch will announce its half-yearly figures for
the period August 1, 01 to January 31, 02 at the end of March 02.Taking into
consideration this consistent re-orientation of the company, the following
budget figures for the Rösch Group (financial year from August 1 to July 31) are
planned:
01/02: sales EUR 4.4 mill, EBIT EUR -14.1 mill (incl. restructuring expenditure)
02/03: sales EUR 12.6 mill, EBIT EUR -1.1 mill
03/04: sales EUR 20.0 mill, EBIT EUR 4.4 mill
Further information: Rösch AG, Tel.: +49 (30) 667915930
end of ad-hoc-announcement (c)DGAP 06.02.2002
——————————————————————————–
WKN: 529 140; ISIN: DE0005291405; Index:
Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, München, Stuttgart, Hannover
060838 Feb 02
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden